In case you missed Friday’s NYT Mini Crossword puzzle, you can find the answers here:
Another day, another Mini Crossword to solve. I’m back after a couple weeks off, and I’m a little late to this due to 4th of July festivities. So without further ado let’s solve this puzzle!
The NYT Mini is a smaller, quicker, more digestible, bite-sized version o

Today's NYT Mini Crossword Clues And Answers For Saturday, July 5th

AstraZeneca has claimed EU approval for its cancer immunotherapy in bladder cancer, a disease that the company has said is central to its growth plans for the product.
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive bladder cancer (MIBC), given in combination with platinum che

AZ claims EU okay for Imfinzi in bladder cancer

ASCO 2025 may be over, but the insights for the future of oncology are only just beginning.
At the American Society of Clinical Oncology’s Annual Meeting this year, pharmaphorum was unable to connect with every expert on the ground in Chicago. However, in a series of conversations post-ASCO, we’ve spoken with some of those whom we missed.
Here, Mic

A look back to ASCO 2025: Industry comments from iOnctura and Asgard Therapeutics

The FDA alerted providers that Abiomed issued updated instructions for use related to all of its Automated Impella Controllers (AICs).
This notice comes as part of the FDA’s Communications Pilot to Enhance the Medical Device Recall Program. The FDA issues these warnings when it becomes aware of a high-risk issue. According to a notice, this issue m

FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

with Charles Duhigg
This episode is your playbook for having saner, smarter, and more successful conversations, even when you disagree.
If every family dinner turns into a debate, and if you feel like you're having the same argument on repeat, you’re not alone.
That’s why Mel called in a world-class expert to give you the blueprint for finally gett

How to Talk to Difficult People: Proven Strategies to Stop Arguments & Feel Connected Again

Dave Durand is currently the CEO of Leading Giants and Executive Chairman of Best Version Media, an international media company located in Brookfield, Wisconsin. During Dave's tenure as CEO, BVM was among the top 20 fastest-growing media companies in North America, and the fastest growing private company in Wisconsin of any type. In 2024, The Wall

Dave Durand

The massive 2025 budget bill, which Congress passed on July 3, would slash safety net programs for older adults, people with disabilities, and their family caregivers, though many of those cuts may not take effect for years. At the same time, the bill would lower taxes for some older adults.
The measure would reduce Medicaid spending by nearly $1 t

What Seniors Need To Know About Congress' Big Budget Bill

As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested

The World's Definitive Degrader & Proximity-Based Drugs Event

CapsoVision announced today that it closed its initial public offering (IPO) and began trading on the Nasdaq Capital Market.
Saratoga, California-based CapsoVision now trades on the Nasdaq under the “CV” ticker as of July 2, 2025. The IPO includes 5.5 million shares of common stock priced at $5 per share.
CapsoVision granted underwriters a 30-day o

Capsule endoscopy tech maker CapsoVision closes IPO

The cell and gene therapies (CGTs) of the 2030s – including the way they are manufactured, delivered, and paid for – will and must look very different than they do today. The long, complex development journey, coupled with reimbursement struggles, has led to a lack of funding and investors turning their attention away from the considerable promises

Cell and gene therapies: Stagnation or maturation?

MiRus announced new early feasibility study results supporting the use of its Siegel transcatheter aortic valve replacement (TAVR) system.
Dr. Pradeep Yadav (Piedmont Heart Institute) and Dr. Raj Makkar (Cedars Sinai) presented findings in podium presentations at NY Valves. Thirty-day results came from the company’s U.S. early feasibility study (EF

MiRus reports positive early feasibility data for heart valve

Philips (NYSE: PHG) has announced it received FDA 510(k) clearance for its deep-learning reconstruction tool, SmartSpeed Precise.
SmartSpeed Precise can scan up to three times faster and produce images up to 80% sharper than earlier methods. The technology is now cleared for clinical use on all Philips 1.5-tesla and 3-tesla MRI systems, including t

Philips wins FDA clearance for AI MRI software SmartSpeed Precise

The latest L&D news, reports, research and updates, personally compiled by TJ’s Editor, Jo Cook. This week: ‘Workcations’ blur holiday boundaries, risking burnout and disconnection. As the line between rest and work vanishes, are we trading true downtime for faux flexibility? Discover how this trend could be undermining your wellbeing.
Degreed’s ne

TJ Newsflash 02 July – AI fairness, frazzled leaders, and fragile managers

An excerpt from Conflict Is an Opportunity: Twenty Fundamental Decisions for Navigating Difficult Times [Association for Conflict Resolution, 2025]
What is my request?
A request is not a sign of submission; it is an empowering investigation tool.
Sometimes, asking if a person is willing to do something, rather than telling them that they should do

The Difference Between Requests and Demands: Using Requests as an Investigative Tool

Spanish captain Irene Paredes will be suspended from their opening match at the UEFA Women’s Euro against Portugal on Thursday as a result of an incident a year ago.
The FC Barcelona defender will not be eligible to play as she serves the second of a two-game suspension for a straight red card she incurred in a match away to Czechia last July. Pare

Irene Paredes Suspended From Spain's Opening Game At UEFA Women's Euro

China has rapidly emerged as a global force in oncology, contributing a significant share of next-generation immunotherapies to the cancer pipeline, including a standout candidate that could rival Merck & Co.’s megablockbuster Keytruda.
Chinese drugs account for 51% of antibody-drug conjugates in development, 48% of bispecific monoclonal antibodies

Can China sustain a surge in oncology drug innovation?

Every night, my husband and I run the same calculation: Should we cook or order out? He’s a mathematician, so he crunches the numbers on what delivery really costs—fees, tips and the waste of groceries already in our fridge. I’m a creative cook, so I scan our pantry for what we already have and whip something up. Most nights, the home-cooked meal w

A home-cooked meal: How we're saving money and building better leaders